secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001000694-24-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q2 net income $162M on $415M revenue; Sanofi partnership boosts cash to $1.1B
--------------------------------------------------------------------------------

- Q2 2024 total revenue $415M (vs. $424M Q2 2023); net income $162M (vs. $58M).
- Received $500M upfront + $70M equity from Sanofi; eligible for up to $700M in milestones plus royalties.
- Ended Q2 with $1.1B cash vs. $584M Dec 2023; combined R&D and SG&A down 34% YoY.
- Filed EUA amendment with FDA for 2024-2025 formula COVID-19 vaccine; BLA accepted with PDUFA April 2025.
- Targeting FY2025 combined R&D/SG&A below $500M; Phase 3 combo/flu vaccine trial starts Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069424000037/0001000694-24-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069424000037/nvax-form8xkq2earnings2024.htm
  HTML page:      https://secwatch.observer/filing/0001000694-24-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer